Galmed issues CEO letter to shareholders

Galmed (GLMD) Pharmaceuticals issued a Letter to Shareholders from Allen Baharaff, Chief Executive Officer. “Over the past year, we have successfully expanded our therapeutic focus beyond liver disease, generating compelling new data that supports a broader clinical development path for Aramchol in oncology and cardiometabolic indications… My message to investors is clear: Galmed is well-capitalized, scientifically advancing on multiple fronts, and positioned for meaningful growth opportunities. 1. Strong Cash Position and Prudent Financial Stewardship. Galmed ended the third quarter of 2025 with approximately $19.2 million in cash and practically zero debt on our balance sheet… 2. Significant Clinical Advancements. Aramchol for MASH and liver fibrosis… Aramchol for Gastrointestinal oncology indications… Expansion Potential Beyond MASH and Oncology… Looking Ahead: In summary, I want to emphasize the following: Galmed remains financially strong, with sufficient resources to support our current strategic and clinical plans. Our scientific progress has been exceptional, with multiple breakthroughs validating and expanding the potential of Aramchol across high-value therapeutic areas. We are committed to short and long-term value creation, grounded in disciplined execution, scientific innovation, and responsible financial stewardship. Throughout this process, we aim to maintain transparency, careful capital allocation, and clear communication with our shareholders.”